Insuvia

Excellence in Pharmacovigilance and Regulatory Affairs

[Insuvia @Insuvia]

Moving prescription medicine to OTC: success depends on clear positioning, consumer education, stakeholder alignment, and a strong go-to market strategy.

Read more about the key factors that can make or break an Rx to OTC switch: https://t.co/Yzj1AfikWp

[Insuvia @Insuvia]

LPPVs have to know local PV activities, support inspections, interact with authorities, maintain oversight of t implementation of the PV system. Without access to right information, fulfilling responsibilities becomes challenging.
https://t.co/8nPriBZm7l

[Insuvia @Insuvia]

Insuvia provides overview of pharmacovigilance requirements across the EAEU and CIS, including the appointment of an EAEU QPPV, local pharmacovigilance roles and local QPPV or Local Safety Representative (LSR) requirements in CIS countries: https://t.co/flvzLsT09n

[Insuvia @Insuvia]

Dossier gap analysis brings clarity by reviewing every module against current CTD and EMA expectations, uncovers outdated data, inconsistencies between modules, missing justifications, compliance issues, local requirements that could delay approval https://t.co/6YVy1VBS7o

[Insuvia @Insuvia]

Licensing-in is fast, but dossiers are rarely submission-ready. Missing assessments, outdated data, and GMP blind spots can derail your launch. Learn how a dossier readiness review protects your timelines and strengthens your negotiation position.
https://t.co/EsHluK7j8S

[Insuvia @Insuvia]

Over 300M people worldwide live with a rare disease- rarity is more common than we think. With 6000+ rare diseases, many face challenges in diagnosis, treatment and care. At Insuvia, we stand with patients, families and carers every day
#RareDiseaseDay #MoreThanYouCanImagine

[Insuvia @Insuvia]

Switching from #Rx to #OTC unlocks opportunities, but it requires the evidence, risk management, communication strategy. https://t.co/ZpiDFL11I7

#RegulatoryAffairs #Pharmaceuticals

[Insuvia @Insuvia]

Affiliates face steady regulatory workloads, outsourcing can help teams stay organized and compliant without stretching internal resources. The right partner can support submissions, updates, and routine tasks so affiliates can focus on local priorities.
https://t.co/oQ86IvqLwN

[Insuvia @Insuvia]

Building a strong #PharmacovigilanceSystem is a critical foundation for #productsafety, compliance, trust. From choosing #safetydatabase to establishing workflows, roles, #qualitycontrols. Well designed #PV system protects both patients and companies.
https://t.co/hMONnfEaPQ

[Insuvia @Insuvia]

#EducationalMaterials are a core element of #aRMM activities in Slovakia and are strictly non‑promotional.
#ŠÚKL established a framework of EM. These materials designed to address specific safety concerns and to complement, not duplicate, the SmPC and PIL.
https://t.co/5s2BuvkqS8

[Insuvia @Insuvia]

#Pharmaceutical marketing operates in highly regulated environment. #Compliance is essential for protecting your brand and avoiding risks.
#Insuvia explains key principles and best practices for creating effective campaigns. https://t.co/HS77Q8nzmO

[Insuvia @Insuvia]

Auditing in #pharmacovigilance is shifting toward smarter strategies. A risk-based approach helps teams prioritize resources, strengthen compliance and enhance patient safety while improving efficiency.

#Insuvia blog: https://t.co/J3r7kiqB1B

[Insuvia @Insuvia]

In Latin America #Pharmacovigilance systems differ in structure, regulatory rigor and alignment with global standards. For MAHs this means #compliance isn’t just a checkbox, it’s a strategic challenge.
https://t.co/JMHT1pgrQG

#Insuvia #PharmaInsights

[Insuvia @Insuvia]

The EU Good Pharmacovigilance Practice Module XVI outlines requirements for developing and evaluating Educational Materials. Once approved with the RMP, materials must be implemented. Local requirements create challenges that can delay product launches.
https://t.co/JfcrDYfPdP

[Insuvia @Insuvia]

#Germany is one of the largest #pharmaceutical markets that #pharmacovigilance regulations reflect both EU and national requirements.
https://t.co/we0qBtj1An

[Insuvia @Insuvia]

#Pharmacovigilance requirements across CIS and EAEU can be complex.
#Insuvia's guide consolidates national regulations for appointing LPPV, helping #pharmaceutical companies and partners navigate diverse compliance expectations with confidence. https://t.co/OOvkNpuCWN

[Insuvia @Insuvia]

When preparing your Decentralized Procedure, the choice of Reference Member State isn’t just a checkbox, it’s a strategic decision that can define your success.
https://t.co/hkLzubHfYX

#PharmaInsights #RegulatoryAffairs #MarketAccess #DCP #RMS #Insuvia

[Insuvia @Insuvia]

A dossier gap analysis is more than just a checklist.
It can strengthen compliance, accelerate review timelines, and improve your chances of regulatory success.
Curious how? Read the full article: https://t.co/WF5IDUBN9l

#Insuvia #RegulatoryInsight #PharmaInsights

[Insuvia @Insuvia]

Right EU regulatory pathway can help you scale across Europe, avoid delays, control regulatory spend, and keep dossiers inspection-ready from day one.
https://t.co/R6Vk6QUA9v: https://t.co/0xb4ZE4COg

#RegulatoryStrategy #EUMarketAccess #PharmaCompliance #Insuvia #RAExcellence

[Insuvia @Insuvia]

National regulations for appointing a LPPV across. MENA region and nearby markets, helping #pharmaceutical companies and their partners navigate complex local expectations with confidence.
https://t.co/Ezp44U5gOJ

#Insuvia #LPPV #LocalPV